-
Invest Dermatol: The golden age of statin therapy for psoriasis is coming?
Time of Update: 2022-08-16
Given the accumulation of evidence that psoriasis accelerates vascular disease, in 2018, the American College of Cardiology/American Heart Association issued landmark guidelines identifying psoriasis as an increased cardiovascular risk factor and recommending that in patients with psoriasis Early statin use (ie, in patients with a 5% 10-year risk of atherosclerotic disease) .
-
Exciting!
Time of Update: 2022-08-16
. This year 's publication of the document " Expert Consensus on Allogeneic Mesenchymal Stem Cell Therapy for Systemic Lupus Erythematosus " means that lupus treatment has a new method for clinical reference.
-
ARD: What is the success rate of discontinuation of glucocorticoids after initial therapy in RA patients?
Time of Update: 2022-08-16
. Methods : A systematic literature search was performed to identify observational cohorts and clinical trials of RA patients receiving initial GC bridging therapy (defined as discontinuation of GC therapy within 1 year) .
-
Learn to judge the signs of bone damage and kill "necrosis" in the cradle!
Time of Update: 2022-08-16
. Currently, disease activity measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score is considered to be the main risk factor for osteonecrosis in early SLE .
-
ARD: Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with more than 2000 patient-year exposures
Time of Update: 2022-08-16
Treatment-emergent adverse events (TEAEs , defined as events that first occurred or worsened in severity after baseline and on or before the last day of the treatment period ) and selected adverse events (AEs) were reported with every 100 The patient-year exposure-adjusted incidence rate (EAIR) was expressed .
-
A&R: Haploinsufficiency of PSMD12 leads to proteasome dysfunction and subclinical autoinflammation
Time of Update: 2022-08-16
42070 Leave a comment here OBJECTIVE : Proteasome-associated autoinflammatory syndrome (PRAAS) is clinically characterized by recurrent fever, neutrophilic skin disease, lipodystrophy, joint contractures, and developmental delay .
-
A&R: Endothelial Activation Antibodies in COVID-19 Patients
Time of Update: 2022-08-16
42094 leave a comment here OBJECTIVE : Endothelial dysfunction is associated with widespread thrombo-inflammatory complications of COVID-19 , with venous thromboembolism being particularly pronounced ( 10-35% ) in severe COVID-19 , and autopsy specimen findings suggest it affects up to 60% of patients , and is associated with COVID-19- related mortality .
-
A&R: Nintedanib slows lung function decline in patients with systemic sclerosis-related interstitial lung disease (ILD)
Time of Update: 2022-08-16
CONCLUSIONS: In the INBUILD trial, nintedanib slowed the rate of FVC decline in patients with progressive fibrotic autoimmune disease-related ILD , and adverse events were manageable in most patients .
-
Daily broadcast of routine blood tests for rheumatoid arthritis
Time of Update: 2022-08-16
Anemia of chronic disease, increased platelet counts, and elevated acute-phase reactants such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are common in patients with active RA Anemia of chronic disease, increased platelet counts, and elevated acute-phase reactants such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are common in patients with active RA .
. leave a message hereleave a message hereleave a message here
-
This "alkali" method of soda water is far from preventing gout!
Time of Update: 2022-08-16
Some time ago , the entry "Can drinking soda water prevent gout?" became popular, arousing curiosity and extensive discussion among the public. Among them, there are many gout patients who "voluntaril
-
The pace of lupus research has never stopped, and these new discoveries are expected to light up the "healing light"!
Time of Update: 2022-08-16
Gene mutation leading to loss of function FcγR IIB is an important receptor on the surface of immune cells, which can bind to IgG-type Fc receptors to exert an immunosuppressive effect.
-
A&R: The role of necroptosis on myofiber death in idiopathic inflammatory myopathy
Time of Update: 2022-08-16
Methods Western blotting and immunohistochemical analysis were performed to examine the expression of receptor-interacting protein 3 (RIP-3) and MLKL proteins , as well as necroptosis -related injury - related molecules in 26 IIM patients and 4 healthy controls.
-
A&R: Longitudinal immune cell profiling in early systemic lupus erythematosus
Time of Update: 2022-08-16
Longitudinal mass spectrometry and multiplex serum cytokine analysis of samples from patients with early SLE revealed that Tfh cells and CXC motif chemokine ligands10 ( CXCL10 ) declined one year after enrollment .
-
A&R: Antibodies to cartilage oligomeric matrix protein (COMP) are pathogenic in mice and may be clinically relevant to rheumatoid arthritis
Time of Update: 2022-08-16
Methods We investigated the pathogenicity of monoclonal anti- COMP antibodies in mice using passive transfer experiments and explored the interaction of anti- immune COMP antibodies with cartilage using immunohistochemical staining .
-
ARD: Increased immunogenicity after a third dose of homologous inactivated SARS-CoV-2 vaccine in a large number of autoimmune rheumatic patients in Brazil
Time of Update: 2022-08-16
Objectives : To determine the immunogenicity of a third dose of CoronaVac vaccine in a large number of patients with autoimmune rheumatic disease (ARD) and factors associated with impaired response .
-
ARD: EULAR points to consider when analyzing and reporting comparative effectiveness studies using observational data in rheumatology
Time of Update: 2022-08-16
, et al Annals of the Rheumatic Diseases 81: Leave a message here OBJECTIVE : Comparing treatment effects in observational settings over time is hindered by several major factors, including confounding and dropout bias .
-
ARD: Prevention of disease flares by risk adaptation stratification of treatment withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial
Time of Update: 2022-08-16
Methods : This multicenter trial (PREVENT-JIA) enrolled 119 patients with JIA in clinical remission , 100 of whom entered the intervention phase to continue or discontinue treatment based on S100A12 and hsCRP levels .
-
ARD: Antibody titers after vaccination predict protection against COVID-19 in patients with autoimmune disease: a survival analysis in a prospective cohort
Time of Update: 2022-08-16
OBJECTIVE : To assess the incidence and risk factors of breakthrough COVID-19 infection in a cohort of vaccinated patients with autoimmune rheumatic diseases (AIRDs) and to determine whether antibodies against the receptor-binding domain (anti-RBD) of the spike protein as a reliable predictor of susceptibility to such infections .
-
A&R: Mechanisms of interleukin-1β-activated microvascular endothelial cells in skin fibrosis in systemic sclerosis
Time of Update: 2022-08-16
OBJECTIVE : To characterize the role of interleukin 1 beta (IL-1 beta ) and microvascular endothelial cells (MVEC) in the generation of alternately activated macrophages in the skin and to investigate their role in systemic sclerosis (SSc , scleroderma ) in the development of skin fibrosis in patients .
-
ARD: What Causes Inconsistency in Outcome Measurements in SLE Clinical Trials?
Time of Update: 2022-08-16
OBJECTIVE : In the anifrolumab (type I interferon receptor monoclonal antibody) systemic lupus erythematosus (SLE) trial program, there is a trial (TULIP-1) in which the BILAG - based Comprehensive Lupus Assessment (BICLA) anifrolumab response was superior to placebo treatment , but the SLE response index (SRI(4)) treatment did not differ significantly .
